| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01371981) | National Cancer Institute (NCI) | 2011-07-06 |
| Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients (NCT01398462) | JW Pharmaceutical | 2011-07-01 |
| ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS (NCT01423175) | Hannover Medical School | 2011-07-01 |
| Preservation of Ovarian Function After Hematopoietic Cell Transplant (NCT01343368) | Masonic Cancer Center, University of Minnesota | 2011-07-01 |
| A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) (NCT01305499) | Hetty Carraway | 2011-07-01 |
| Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies (NCT01399840) | Pfizer | 2011-06-30 |
| Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) (NCT01352650) | Weill Medical College of Cornell University | 2011-06-17 |
| The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia (NCT01065545) | Northwestern University | 2011-06-01 |
| Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (NCT01361334) | University Hospital Muenster | 2011-06-01 |
| An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy (NCT01446081) | University Health Network, Toronto | 2011-06-01 |
| Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) (NCT02101983) | University of Rochester | 2011-05-01 |
| Haploidentical NK-cell Infusion in Acute Myeloid Leukemia (NCT01947322) | Assistance Publique - Hôpitaux de Paris | 2011-05-01 |
| Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia (NCT01307579) | Children's Oncology Group | 2011-04-04 |
| Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML) (NCT01329471) | Hillel Yaffe Medical Center | 2011-04-01 |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (NCT01344876) | Otsuka Pharmaceutical Co., Ltd. | 2011-04-01 |
| Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia (NCT01332786) | University Health Network, Toronto | 2011-03-01 |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia (NCT01297543) | Cellerant Therapeutics | 2011-03-01 |
| Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT01295307) | Technische Universität Dresden | 2011-03-01 |
| Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients (NCT01149408) | University of Utah | 2011-02-01 |
| Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01252667) | Fred Hutchinson Cancer Center | 2011-01-25 |
| WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (NCT01266083) | Sellas Life Sciences Group | 2011-01-14 |
| Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) (NCT01451268) | Johann Wolfgang Goethe University Hospital | 2011-01-01 |
| Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) (NCT01301820) | French Innovative Leukemia Organisation | 2011-01-01 |
| Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01280786) | Synta Pharmaceuticals Corp. | 2011-01-01 |
| Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML (NCT01277484) | Seoul St. Mary's Hospital | 2011-01-01 |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (NCT01191801) | Sunesis Pharmaceuticals | 2010-12-17 |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211) | National Cancer Institute (NCI) | 2010-12-14 |
| Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients (NCT05188326) | Associazione Qol-one | 2010-11-28 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy (NCT02024308) | Changhai Hospital | 2010-11-01 |
| Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia (NCT01222143) | University Health Network, Toronto | 2010-10-01 |
| Telomere and Telomerase (NCT01176422) | University of Kansas Medical Center | 2010-09-01 |
| PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias (NCT01169012) | UNC Lineberger Comprehensive Cancer Center | 2010-09-01 |
| Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP) (NCT01203033) | West Virginia University | 2010-09-01 |
| Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure (NCT01133886) | King's College London | 2010-09-01 |
| Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML) (NCT01195506) | Taipei Medical University WanFang Hospital | 2010-09-01 |
| Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia (NCT01174888) | Alison Walker | 2010-08-01 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219) | National Cancer Institute (NCI) | 2010-07-15 |
| Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor (NCT01350245) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2010-07-01 |
| Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) (NCT01211457) | Cyclacel Pharmaceuticals, Inc. | 2010-06-17 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia (NCT01139970) | National Cancer Institute (NCI) | 2010-06-04 |
| Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) (NCT01074047) | Celgene | 2010-06-01 |
| Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia (NCT01180426) | Chroma Therapeutics | 2010-06-01 |
| Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy (NCT01170598) | Toronto Rehabilitation Institute | 2010-06-01 |
| Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia (NCT01141673) | Taipei Medical University WanFang Hospital | 2010-06-01 |
| Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia (NCT00615784) | Abramson Cancer Center at Penn Medicine | 2010-05-25 |
| Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation (NCT00893399) | University of Ulm | 2010-05-12 |
| Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection (NCT01141543) | University Health Network, Toronto | 2010-05-01 |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation (NCT01068301) | St. Jude Children's Research Hospital | 2010-05-01 |
| Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome (NCT01075425) | Virginia Commonwealth University | 2010-05-01 |
| ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) (NCT01067274) | Acute Leukemia French Association | 2010-04-01 |
| Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival (NCT01188330) | Institut Paoli-Calmettes | 2010-03-01 |
| Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia (NCT02277847) | Guangdong Provincial People's Hospital | 2010-03-01 |
| Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia (NCT01130662) | University of Kansas | 2010-03-01 |
| Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (NCT00636922) | Bayside Health | 2010-02-01 |
| Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. (NCT01041508) | Therapeutic Advances in Childhood Leukemia Consortium | 2010-01-29 |
| Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1) (NCT01146977) | Cooperative Study Group A for Hematology | 2010-01-01 |
| A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia (NCT01034410) | Antisoma Research | 2010-01-01 |
| A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00861874) | University of Rochester | 2010-01-01 |
| Pre-hospital Risk Factors for Invasive Fungal Infection (NCT01315925) | Catholic University of the Sacred Heart | 2010-01-01 |
| Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation (NCT01608204) | Rambam Health Care Campus | 2010-01-01 |
| Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia (NCT01056523) | Jewish General Hospital | 2010-01-01 |
| Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction (NCT01025154) | M.D. Anderson Cancer Center | 2010-01-01 |
| Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients (NCT03150134) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2010-01-01 |
| 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia (NCT01587430) | National Research Center for Hematology, Russia | 2010-01-01 |
| Single Dose Study With 4SC-203 in Healthy Volunteers (NCT01054937) | 4SC AG | 2010-01-01 |
| A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) (NCT01066494) | Antisoma Research | 2010-01-01 |
| Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma (NCT00965224) | Zwi Berneman | 2010-01-01 |
| HCT Versus CT in Elderly AML (NCT00766779) | European Society for Blood and Marrow Transplantation | 2010-01-01 |
| A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). (NCT00946647) | Novartis Pharmaceuticals | 2009-12-02 |
| Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia (NCT01025778) | Lund University Hospital | 2009-12-01 |
| A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia (NCT01035502) | Clavis Pharma | 2009-12-01 |
| Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00990054) | Genzyme, a Sanofi Company | 2009-12-01 |
| Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen (NCT01048827) | University of California, San Francisco | 2009-11-01 |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (NCT00989261) | Daiichi Sankyo | 2009-11-01 |
| Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (NCT00780598) | Chroma Therapeutics | 2009-10-01 |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy (NCT00990587) | University Health Network, Toronto | 2009-10-01 |
| A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies (NCT01036009) | University of California, San Francisco | 2009-10-01 |
| A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (NCT01055483) | Novartis Pharmaceuticals | 2009-09-01 |
| A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia (NCT00866281) | Novartis Pharmaceuticals | 2009-09-01 |
| Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies (NCT00908167) | St. Jude Children's Research Hospital | 2009-09-01 |
| Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia (NCT00969891) | Mikkel Krogh-Madsen | 2009-09-01 |
| Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (NCT00988013) | University of Illinois at Chicago | 2009-09-01 |
| Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy (NCT00963495) | University Health Network, Toronto | 2009-08-01 |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia (NCT00964873) | Synta Pharmaceuticals Corp. | 2009-08-01 |
| T-cell Depleted Alternative Donor Transplantation (NCT00968864) | Wake Forest University Health Sciences | 2009-08-01 |
| Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT00915252) | University Hospital Muenster | 2009-07-01 |
| Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia (NCT01347996) | Cytovia, Inc. | 2009-07-01 |
| Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML) (NCT01382147) | Prof. Dr. Wolfgang Hiddemann | 2009-07-01 |
| Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients (NCT00952588) | AstraZeneca | 2009-07-01 |
| Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) (NCT00831766) | H. Lee Moffitt Cancer Center and Research Institute | 2009-06-25 |
| Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia (NCT00961142) | University Hospital Tuebingen | 2009-06-01 |
| Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) (NCT00926731) | AstraZeneca | 2009-06-01 |
| PRO#0118: Decitabine Plus Mini Flu-Bu (NCT01455506) | Hackensack Meridian Health | 2009-05-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial) (NCT00932412) | Hospices Civils de Lyon | 2009-03-01 |
| Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (NCT03961919) | Ciceri Fabio | 2009-02-10 |
| Registry on Hypomethylating Agents in Myeloid Neoplasms (NCT01595295) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2009-02-09 |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) (NCT00822094) | Jazz Pharmaceuticals | 2009-02-01 |
| A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (NCT00885508) | Groupe Francophone des Myelodysplasies | 2009-02-01 |